[Should ophtalmologists recommend medical cannabis to patients with glaucoma?]

Ugeskr Laeger. 2018 Jul 16;180(29):V11170861.
[Article in Danish]

Abstract

Cannabis has been widely used for various medical purposes since before year 2000 BC. Its effects are mediated by cannabinoids and stimulation of mainly G-protein coupled cannabinoid receptors. In 1971, subjects who smoked marihuana, showed a decrease in the intraocular pressure. Later investigations additionally revealed a neuroprotective effect of both ∆-9-tetrahydrocannabinol and cannabidiol (CBD). Furthermore, CBD was found to promote neurogenesis. The aim of this review is to provide an overview of the potential use of cannabinoids in the treatment of glaucoma.

Publication types

  • Review

MeSH terms

  • Cannabidiol / chemistry
  • Cannabidiol / pharmacology
  • Cannabidiol / therapeutic use
  • Cannabinoids / pharmacology
  • Cannabinoids / therapeutic use
  • Glaucoma / drug therapy*
  • Humans
  • Intraocular Pressure / drug effects
  • Medical Marijuana / pharmacology
  • Medical Marijuana / therapeutic use*
  • Neuroprotection / drug effects
  • Retina / drug effects

Substances

  • Cannabinoids
  • Medical Marijuana
  • Cannabidiol